Bio-Path Hopes To Blaze Profitable Path With Antisense Drugs
Executive Summary
Bio-Path Holdings is trying to become the next company to make it big with antisense drugs. Recently, the Houston-based biotech released data showing its lead compound, which is known as BP-1001, may hold promise in treating advanced acute myeloid leukemia, or AML.
You may also be interested in...
The John Green Effect: Will Industry Be Influenced Again?
Drug and device makers regularly use media to sway consumers. But some advocacy groups recently turned the tables by using social media to sway industry.
Pressure Mounts On Pharma To Act On Environmental Targets
There are growing demands from government officials, investors and employees for the pharmaceutical industry to reduce emissions and waste, and – most of all – make environmental sustainability a core part of its business.
Would You Like Chips With That? High-Tech Alternatives Could Replace Animal Testing
The FDA Modernization Act 2.0 should make it easier for companies to gain regulatory authorization using non-traditional testing methods, like organs-on-a-chip. But biopharma will need to make the leap into technology to help build knowledge and data if the drug development world is to move away from animal testing entirely.